司帕沙星和洛美沙星的随机对照临床研究

Randomized Controlled Clinical Study of Sparfloxacin Compared with Lomefloxacin

司帕沙星是一种消除半衰期长 ,组织渗透力强 ,抗菌谱广的新型喹诺酮类抗菌药物。本文以洛美沙星为对照药 ,采用随机对照试验考察国产司帕沙星的临床疗效和不良反应。司帕沙星 2 0 0mgQD疗程 5～ 10天 ,治疗呼吸系统、泌尿系统、皮肤软组织、烧伤创面感染以及伤寒等共 45例 ,临床痊愈率和有效率为 77 78%和91 11% ;对照药洛美沙星治疗各种感染的临床痊愈率和有效率为 6 7 44 %和 86 6 5 % (P >0 0 5 ) ;司帕沙星治疗组细菌清除率和阴转率为 92 5 0 %和 92 30 % ;洛美沙星组为 86 84%和 86 49% (P >0 0 5 ) ;所分离的临床分离株对司帕沙星的敏感率为 93 5 9% ,对照组为 91 0 3% (P >0 0 5 )。由上可知 ,司帕沙星是一种使用方便 ,可用于治疗各系统感染、安全有效的抗感染药物。

Sparfloxacin is a new fluroquinolones which has a long half-life time,perfect tissue penetration,broad spectrum.Sparfloxacin was evaluated the clinical efficacy and adverse reaction events,compared with lomefloxacin in randomized controlled study.Sparfl oxacin was administr ated for treating 45 patients with the respiratory infection,urinary infection,skin and soft tissue infection,and burn skin infection et al,in 200mg QD×5～10 days.The clinical cure rate and effective rate were 77 78% and 91 11%,those of lomefl oxacin were 67 44% and 86 65%( P >0 05).The bacteria eliminate rate and negative change's rate of sparfloxacin treat group were 92 50% and 92 30%,those of lomefloxacin were 86 85% and 86 49%( P >0 05).The susceptibility of the clinical bacteria to sparfloxacin and lomefloxacin were 93 59% and 91 03%( P >0 05).From the result,sparfloxacin is a convenient,safe and effective antimicrobial agents.